Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- In Part 1 of the trial, you must be between 18 and 90 years old; in Part 2, you must be between 13 and 90 years old
- You have been diagnosed with leukemia or lymphoma that has come back after treatment or has not responded to treatment, as defined by the trial's specific guidelines
- Your cancer cells must test positive for a protein called CD19
- You must have a low enough level of antibodies to a specific virus used in the treatment (called AAV) in your blood (confirm with trial site)
- Your kidneys, liver, heart, and lungs must be functioning within the ranges required by the trial
- Your blood cell counts and related measurements must fall within the ranges required by the trial
Who may not be able to join:
- You have signs of liver stress, shown by elevated levels of certain liver enzymes in your blood (confirm with trial site)
- You have a history of a blood vessel disorder called thrombotic microangiopathy, a heart muscle disease called cardiomyopathy, or you currently have problems with nerve sensitivity or sensation
- You are currently pregnant or breastfeeding
- You have moderate to severe acute Graft versus Host Disease (a complication sometimes seen after transplants), or any level of chronic Graft versus Host Disease
- You have a history of being allergic to steroid medications, or have had serious side effects from them in the past
- You have received chemotherapy too recently before joining the trial, within timeframes set out by the trial guidelines
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Vironexis Clinical Trials, Vironexis Biotherapeutics Inc.
Phone: 908-938-6019
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Treatment emergent adverse events (TEAEs) and treatment-emergent serious events (TESAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.